Nature Reviews Rheumatology - Table of Contents alert Volume 9 Issue 3

TABLE OF CONTENTS
March 2013 Volume 9 Number 3
Impact Factor 8.388 *	In this issue Research Highlights News and Views Reviews Also this month  Web focus: Rational therapy in RA
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
Nature Reviews Immunology Focus on The inbetweeners: innate-like lymphocytes This Focus issue features Review and Perspective articles on the 'inbetweeners' of the immune system, and a Guidelines article proposing a uniform nomenclature for the emerging innate lymphoid cell subsets. Read the Focus online at: www.nature.com/nri/focus/innate-likelymphocytes
RESEARCH HIGHLIGHTS Top Paediatric rheumatology: The immaturity of the SLE responder index in paediatric SLE Published online: 19 February 2013 p133 | doi:10.1038/nrrheum.2013.23 PDF Rheumatoid arthritis: Cell sorting to sort cause from effect in RA epigenetics Published online: 05 February 2013 p134 | doi:10.1038/nrrheum.2013.15 PDF Metabolic bone diseases: Building bone is best in glucocorticoid-induced osteoporosis Published online: 05 February 2013 p135 | doi:10.1038/nrrheum.2013.16 PDF Regenerative medicine: Adhesive-hydrogel composite developed to repair damaged cartilage Published online: 29 January 2013 p135 | doi:10.1038/nrrheum.2013.9 PDF Experimental arthritis: iRHOM2—a new potential therapeutic target for inflammatory arthritis Published online: 12 February 2013 p136 | doi:10.1038/nrrheum.2013.19 PDF Degenerative disc disease: Altered Wnt signalling in intervertebral disc degeneration Published online: 12 February 2013 p136 | doi:10.1038/nrrheum.2013.22 PDF IN BRIEF Osteoarthritis: Vitamin D does not slow progression of knee OA | Connective tissue diseases: Finding the best dosing regimen for epratuzumab | Pain: Gastrointestinal safety of celecoxib | Undifferentiated arthritis: 5-year outcomes of early intervention for 'probable RA' PDF Rheumatology JOBS of the week Postdoctoral Fellow University of Pittsburgh-Dept of Rheumatology & Clinical Immunology Career Development Fellowships Arthritis Research UK More Science jobs from Rheumatology EVENT 2nd International Conference & Exhibition on Orthopedics and Rheumatology 19.-21.08.13 Las Vegas, US More science events from
NEWS AND VIEWS		Top
Rational therapy in RA: Issues in implementing a treat-to-target approach in RA Marc D. Cohen & Edward C. Keystone Published online: 12 February 2013 p137 | doi:10.1038/nrrheum.2013.18 The treat-to-target approach has been a major breakthrough in the treatment of rheumatoid arthritis. Although this strategy has been evaluated in many clinical studies, whether a high level of adherence is feasible in real-world clinical practice remains uncertain. Full Text | PDF
Autoimmunity: Will worms cure rheumatoid arthritis? Dana Ben-Ami Shor & Yehuda Shoenfeld Published online: 29 January 2013 p138 | doi:10.1038/nrrheum.2013.3 Evolving understanding of the role of helminths in the pathogenesis of autoimmunity has led to the development of novel therapeutic interventions that are showing promise in patients with immune-mediated diseases. Meanwhile, studies in animal models of arthritis suggest that these new products might also be applicable in autoimmune rheumatic disease. Full Text | PDF | Supplementary information
Focus on: Rational therapy in RA REVIEWS Top Genetics and epigenetics of rheumatoid arthritis Sebastien Viatte, Darren Plant & Soumya Raychaudhuri Published online: 05 February 2013 p141 | doi:10.1038/nrrheum.2012.237 A rational approach to the management of rheumatoid arthritis (RA) begins with understanding the disease, development of which can be influenced by environmental, genetic and epigenetic factors. Genetic and epigenetic data in RA are revealing insights into pathogenesis and revitalizing the shared epitope hypothesis. These advances are discussed in this Review, alongside approaches to integrating the findings of genetic and functional studies. Abstract | Full Text | PDF The problem of choice: current biologic agents and future prospects in RA Ernest H. Choy, Arthur F. Kavanaugh & Simon A. Jones Published online: 19 February 2013 p154 | doi:10.1038/nrrheum.2013.8 Undoubtedly, biologic agents have altered the landscape of therapeutic options for patients with rheumatoid arthritis (RA). Nevertheless, the choice can be bewildering, especially as several different molecules and pathways are the targets of approved and developmental therapies in RA. The authors of this Review provide a guide to navigate the current options and to understand how the picture is likely to evolve in the near future. Abstract | Full Text | PDF Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis Pauline A. van Schouwenburg, Theo Rispens & Gerrit Jan Wolbink Published online: 12 February 2013 p164 | doi:10.1038/nrrheum.2013.4 The presence of anti-drug antibodies (ADA) can result in the loss of response to anti-TNF biologic agents in patients with rheumatoid arthritis. In this article, van Schouwenburg et al. outline the limitations of current assays for ADA detection and discuss how studying the immune responses caused by the different anti-TNF biologic agents could lead to strategies to help reduce or prevent the development of ADA. Abstract | Full Text | PDF Back to the future: oral targeted therapy for RA and other autoimmune diseases John J. O'Shea, Arian Laurence & Iain B. McInnes Published online: 19 February 2013 p173 | doi:10.1038/nrrheum.2013.7 Advances in our understanding of immune cell receptors and the development of biologic agents targeting them have revolutionized the treatment of rheumatoid arthritis (RA). Now, inhibitors of kinases integral to the signalling pathways downstream of these receptors have been added to the therapeutic armamentarium. This Review discusses the signalling pathways and small-molecule inhibitors of their component kinases that have already shown, or are predicted to show, promise in the treatment of RA. Abstract | Full Text | PDF Creative trial design in RA: optimizing patient outcomes Maya H. Buch, Sue Pavitt, Mahesh Parmar & Paul Emery Published online: 05 February 2013 p183 | doi:10.1038/nrrheum.2013.5 Drug development, underpinned by randomized controlled trials, has greatly advanced the the treatment of rheumatoid arthritis (RA). However, modern principles and goals of RA management raise new challenges and call into question the appropriateness of traditional trial designs. This Review discusses these designs and the associated challenges, and outlines opportunities that arise from innovative trial designs. Abstract | Full Text | PDF
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*Journal Citation Reports, Thomson, 2011. Nature Reviews Rheumatology was previously published as Nature Clinical Practice Rheumatology.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2013 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.